Lokavant, a Princeton, NJ-based clinical trial intelligence company raised $21M in funding.
The round was led by Edison Partners with participation from Roivant Sciences (Nasdaq: ROIV). As part of the transaction, Edison’s General Partner, Gregg Michaelson, will join Lokavant’s board of directors.
The company intends to use the funds to scale its commercial teams, and accelerate feature development for its platform, which provides intelligence for clinical trials from planning to execution
Led by CEO Rohit Nambisan, Lokavant is a clinical intelligence platform that enables the real-time integration and harmonization of all clinical trial data for study planning and operations. The solution aggregates and integrates real-time data from disparate trial data sources, and powers advanced analytics enabled by its compendium of proprietary trial data. The suite of applications built on the system allows study teams to proactively plan and manage their studies and surface insights, driving efficiencies in all scientific and operational use cases. Clinical researchers access the platform via use-case-specific applications, with a product portfolio encompassing data-driven study planning, benchmarking, operational health assessments, risk detection, medical monitoring, and vendor oversight, all incorporating Lokavant’s proprietary data set into planning and monitoring.
FinSMEs
07/12/2022